- Familial pheochromocytoma
- Carotid body tumor
- Turkish family
Objective: This is a report of 2 hypertensive siblings with a history of carotid body tumors and subsequent benign adrenal pheochromocytomas (pheos) in a family where the mother had died of possible adrenal carcinoma. Clinical Presentation and Intervention: The first case was a 35-year-old woman with paroxysmal hypertensive attacks and a right adrenal mass. She had earlier undergone surgery to remove bilateral carotid body tumors. Investigation revealed excessive excretion of catecholamines and their metabolites in the urine. Abdominal MRI and 131I-MIBG scintigraphy revealed a right adrenal tumor. Right adrenalectomy was performed. The second case, the 45-year-old brother of the first case, was found to have a left adrenal mass on abdominal MRI. Catecholamines and their metabolites in the urine were found to be increased. He had also had surgery to remove bilateral carotid body tumors of the neck. Left adrenalectomy was performed. Both siblings showed no evidence of other familial syndromes, such as multiple neoplasia type 2, von Hippel-Lindau disease or neurofibromatosis type 1. Conclusion: Although the combination of familial carotid body tumors and pheo is rare, a patient who remains hypertensive after removal of a carotid body tumor deserves a careful evaluation to exclude pheo. Such tumors may be extra-adrenal or multifocal.
Copyright © 2006 S. Karger AG, Basel
- Astuti D, Latif F, Dallol A, Dahia PLM, Douglas F, George E, Sköldberg F, Husebye ES, Eng C, Maher ER: Gene mutations in the succinate dehydrogenase subunit SDHB, cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001;69:49–54.
- Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS: Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134:315–329.
- Neumann HP, Bausch B, McWhinney SR, et al: Genetic germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346:1459–1466.
- Pritchett JW: Familial concurrence of carotid body tumor and pheochromocytoma. Cancer 1982;49:2578–2579.
- Doppman JL, Reinig JW, Dweyer AJ, et al: Differentiation of adrenal masses by magnetic resonance imaging. Surgery 1987;102:1018–1026.
- Sheps SG, Jiang NS, Klee GG, van Heerden JA: Recent developments in the diagnosis and treatment in pheochromocytoma. Mayo Clin Proc 1990;65:88–99.
- Walther MM, Keiser HR, Linehan WM: Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 1999;17:35–39.
- Shapiro B, Fig LM: Management of pheochromocytoma. Endocrinol Metab Clin North Am 1989;18:443–481.
- Maher ER, Eng C: The pressure rises: update on the genetics of phaeochromocytoma. Hum Mol Genet 2002;11:2347–2354.
- Baysal BE, Ferrell RE, Willett-Brozick JE, et al: Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000;287:848–851.
- Astuti D, Hart-Holden N, Latif F, et al: Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol 2003;59:729–733.
- Neumann HP, Pawlu C, Peczkowska M, et al: Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943–951.
Dr. Cihangir Erem
Karadeniz Technical University Tıp Fakültesi
İç Hastalıkları Anabilim Dalı
TR–61080 Trabzon (Turkey)
Tel. +90 462 377 5449, Fax +90 462 325 2270, E-Mail email@example.com
Received: March 21, 2005
Revised: November 28, 2005
Number of Print Pages : 5
Number of Figures : 3, Number of Tables : 0, Number of References : 12
Medical Principles and Practice (International Journal of the Kuwait University Health Sciences Centre)
Vol. 15, No. 5, Year 2006 (Cover Date: August 2006)
Journal Editor: Al-Zaid, N.S. (Kuwait)
ISSN: 1011–7571 (print), 1423–0151 (Online)
For additional information: http://www.karger.com/MPP
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license
), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.